Estrogen-related Receptor Gamma (ERRγ; NR3B3)
| Product Family | Product Number | Product Description | Technical Manual |
| IB0802 ERRγ (NR3B3) |
IB08021-32 | Human ERRγ Reporter Assay System, 3 x 32 assays in 96-well format | Technical Manual |
| IB08021 | Human ERRγ Reporter Assay System, 1 x 96-well format assays | Technical Manual | |
| IB08022 | Human ERRγ Reporter Assay System, 1 x 384-well format assays |
Estrogen-related Receptor Gamma Assay Kit 
This Estrogen-related Receptor Gamma (ERRγ) assay kit is an all-inclusive ERR gamma reporter assay system that includes, in addition to ERRγ Reporter Cells, two optimized media for use during cell culture and (optionally) in diluting the test samples, a reference inverse-agonist, Luciferase Detection Reagent, a cell culture-ready assay plate, and a detailed protocol.
ERRγ Reporter Cells are prepared using INDIGO’s proprietary CryoMite™ process. This cryo-preservation method yields high cell viability post-thaw, and provides the convenience of immediately dispensing healthy, division-competent reporter cells into assay plates. There is no need for intermediate spin-and-wash steps, viability determinations, or cell titer adjustments.
INDIGO’s ERRγ assay kits feature a luciferase detection reagent specially formulated to provide stable light emission between 5 and 90+ minutes after initiating the luciferase reaction. Incorporating a 5-minute reaction-rest period ensures that light emission profiles attain maximal stability, thereby allowing assay plates to be processed in batch. By doing so, the signal output from all sample wells, from one plate to the next, may be directly compared within an experimental set.
ERRγ Assay Kits are offered in different assay formats to accommodate researchers’ needs: 3 x 32, 1 x 96, and 1 x 384 assay formats for screening small numbers of test compounds, as well as custom bulk reagents for HTS applications.
Bulk assay reagents can be custom manufactured to accommodate any scale of HTS. Please inquire.
Estrogen-related Receptor Gamma Assay Services
The primary application of INDIGO’s cell-based nuclear receptor assays are to quantitatively assess the bioactivity of a test compound as an agonist (activator) or antagonist (inhibition of an agonist response) of a given receptor. Service assays include a positive control reference compound and ‘vehicle’ control for every experiment. A formal study report and all data files are provided to the client upon completion of the study. To receive a quote for your proposed study, complete & submit the online “Request a Quote” form or contact an INDIGO Customer Service Representative to discuss your desired study parameters.
Estrogen-related Receptor Gamma Background
INDIGO's Estrogen-related Receptor Gamma cell-based assay systems utilize proprietary mammalian cells engineered to provide high-level expression of a hybrid form of Human ERRγ (also known as NR3B3).
Reporter Cells also incorporate a responsive luciferase reporter gene. Quantifying expressed luciferase activity at the assay endpoint provides a sensitive surrogate measure of changes in ERRγ activity in treated cells. As is true in vivo, these reporter cells express ERRγ in a constitutive state of high-level activity in the putative absence of bound ligand. Interestingly, the ligand binding domain of ERRγ may be occupied by a ligand that produces further elevation of the receptor’s constitutive activity (an agonist response). Alternatively, ERRγ may have ligand-binding interactions that results in the loss of constitutive active (an inverse-agonist response).
Therefore, the principle application of this assay system is in the screening of test samples to quantify the agonist or inverse-agonist activities that they may exert against human ERRγ.
For more information on ERRγ, visit the Nuclear Receptor Resource.
Synonyms:Estrogen-related Receptor Beta, ERRγ, ERR gamma, ERRg, Human Estrogen-related Receptor Gamma, Human ERR gamma, NR3B3
Estrogen-related Receptor Gamma Assay Data
Dose-response analyses of Human ERRγ. ERRγ Assays were performed using A.) the reference agonists GSK4716 and DY131 (Tocris), and B.) the inverse-agonists 4-Hydroxy Tamoxifen (provided), DY40 and DY181. INDIGO’s Live Cell Multiplex assay confirmed that none of the treatment concentrations induced cytotoxicity (data not shown).Averaged relative light units (RLU) and their corresponding values of standard deviation and percent coefficient of variation were determined for each treatment concentration (n = 3). Values of fold-activation (F/A) and fold-reduction (F/R) in ERRγ activities were calculated by normalizing respective RLU values from test compound-treated reporter cells to the RLU value of untreated reporter cells. Z’ values were calculated as described by Zhang, et al. (1999). Non-linear regression and respective EC50 and IC50 determination were performed using GraphPad Prism software.
Estrogen-related Receptor Gamma Assay Research Areas
Cancer; Cardiovascular Disease; Endocrinology; Steroid Receptor; Osteoporosis; Fertility; Alzheimer’s Disease; Reproduction and Development; Environmental Toxicology